Key facts
- It has raised $48.0M; the latest was Later Stage VC ($30.0M) in Dec 2025.
- Notable investors include HSG (Hong Kong), OrbiMed, Lapam Capital, Hankang Capital, Ennovation Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Proviva Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Proviva Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Proviva Therapeutics
Developer of pharmaceutical technology platform intended for anti-tumor immunity. The company develops a prodrug technology platform that can achieve specific release of cytokines in the tumor microenvironment, enabling medical users improve the efficacy and safety of tumor treatment.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Employees
- 2
- Website
- provivatx.cn/
- Ownership
- Privately Held (backing)
Proviva Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Proviva Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Proviva Therapeutics in its N-PORT filings yet. We sweep new filings monthly.